주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요 새 탭/창에서 열기

Elsevier
엘스비어와 함께 출판

Cancer Research UK

Elsevier has confirmed with Cancer Research UK 새 탭/창에서 열기 how authors publishing in Elsevier journals can comply with their open access policy. 새 탭/창에서 열기 Details of how to comply are outlined below.

Policies

Cancer Research UK requires electronic copies of any research articles that have been accepted for publication in a peer-reviewed journal to be made available through Europe PubMed Central (Europe PMC) as soon as possible, and no later than six months, after final publication.

Authors can comply by publishing gold open access in either an Elsevier open access or hybrid journal after paying an APC, or by publishing subscription and using the green open access route in any journal which allows authors to self-archive their accepted manuscripts in Europe PMC after an embargo period of no more than six months. Articles accepted for final publication on or after 1 January 2022 will be required to be made openly-available in Europe PMC immediately on publication.

Authors can choose to publish gold open access in Elsevier’s open access or hybrid journals. This includes journals published by The Lancet. When publishing open access, the corresponding author will be given a choice of two Creative Commons licenses. Cancer Research UK policy states that authors are required to select a Creative Commons Attribution (CC BY) 4.0 license.

An article publication charge (APC) is required to be paid in order to make an article open access. Elsevier's APCs range between circa US $150 and c$9,900, excluding tax, and are journal specific. Please refer to the guide for authors on the journal homepage for more information.

Cancer Research UK provides designated funds to support the payment of APCs through block grants to institutions. Authors should apply to their host institutions to access these funds.

Upon final publication, Elsevier will immediately send to Europe PMC the final published journal article (PJA) as it appears on ScienceDirect. Europe PMC should link back to the final version of the article hosted on ScienceDirect, via its DOI, so that the article can be cited.

Cancer Research UK-funded authors who do not have funds available for gold open access can self-archive their accepted manuscript on Europe PMC after the embargo period for their specific journal has expired. Accepted manuscripts must include a link back to the final published article on ScienceDirect. Please see our sharing policy for more information.

Help and support